tbuckley/cabot-search huggingface dataset:
Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
Authors: E. van Cutsem, R. Labianca, D. Hossfeld, G. Bodoky, A. Roth, E. Aranda, B. Nordlinger, S. Assadourian, K. Wang, D. Cunningham
Journal: Journal of Clinical Oncology (2005)

LBA8 Background: Infused irinotecan regimens have improved survival in metastatic CRC. This international, multicenter, open-label, randomized, prospective trial of adjuvant chemotherapy with IF vs. F was designed to confirm these results in pts with stage III colon cancer. Pts were given IF (Arm A) or F (Arm B) in 4 cycles of 3 infusions every 2 weeks (de Gramont regimen) or 4 cycles of the AIO regimen. Irinotecan was given as 180 mg/m2 per dose in the de Gramont regimen, and as 80 mg/m2 in the AIO regimen. Methods: Inclusion criteria were WHO performance status <2, and stage III disease (UICC criteria). Exclusion criteria were prior treatment with chemotherapy, and rectal cancer. The primary endpoint is the comparison of 3-year disease-free survival in stage III pts who received IF vs. F in the de Gramont regimen, using the log-rank test. A total of 2014 Stage III pts were to be randomized in order to obtain the 452 events calculated to guarantee 90% power to detect an increase in 3 yr DFS from 70% to 77% in Arm A (hazard ratio 1.36). The DFS and RFS curves will also be estimated using Kaplan-Meier methodology. Cox models will be used to analyze the influence of selected variables. Secondary endpoints include relapse-free survival, overall survival, safety, and potential prognostic markers. Results: Between Jan 2000 and April 2002, 2124 pts from 28 countries were randomized and 2101 pts treated. Tumor blocks from 1500 pts were collected for translational research. The two arms were well balanced - median age 60 (19–76), 55% male, 99% WHO PS <2. Median follow-up was 31 months. Selected grade 3/4 toxicities (%) in Arms A/B respectively were: myelosuppresion (1 vs. 0.3%) diarrhea (12 vs. 6%), venous thrombosis (7 vs. 5%), infection (2 vs. 0.2%). Conclusions: The primary endpoint will be analyzed before March 25, 2005 and will be presented at the ASCO meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer, sanofi-aventis Pfizer, sanofi-aventis sanofi-aventis sanofi-aventis
Transportation of children on extracorporeal membrane oxygenation: one-year experience of the first neonatal and paediatric mobile ECMO team in the north of France
Authors: J. Rambaud, P. L. Léger, M. Larroquet, A. Amblard, N. Lodé, J. Guilbert, S. Jean, I. Guellec, I. Casadevall, K. Kessous, H. Walti, R. Carbajal
Journal: Intensive Care Medicine (2015)
Supportive Therapies in Multiple Myeloma
Authors: Charise Gleason, Ajay Nooka, Sagar Lonial
Journal: Journal of the National Comprehensive Cancer Network (2009)

The outlook for patients with myeloma has improved dramatically over the past few years largely because of improvements in supportive care, the use of high-dose therapy, and the introduction of the novel agents thalidomide, bortezomib, and lenalidomide. These new treatment options have changed the natural history for patients with myeloma, but clinicians must consider treatment-related toxicities. Some of the most common short- and long-term toxicities include the development of peripheral neuropathy, hematologic complications, thrombosis, and bone-related complications, such as fracture and osteonecrosis of the jaw. Careful consideration of patient-reported symptoms and appropriate dose modification or prophylaxis to prevent the development of toxicity are critical, and will result in improved quality of life and better tolerance of delivered therapy.
PET/CT fusion in radiotherapy treatment planning for head and neck cancer
Authors: Z. Xiang
Journal: Journal of Clinical Oncology (2009)

e17046 Background: Positron emission tomography/computerized emission tomography (PET/CT) creates fusion images which are a combination of tissue function (PET) and anatomy (CT). It is playing an increasingly important role in radiotherapy of cancer. Aim of this report is to investigate the value of PET/CT fusion in radiotherapy treatment planning for head and neck cancer. Methods: 17 patients with head and neck cancer underwent 18 F-FDG PET/CT imaging. The primary lesions were all proved by pathology. PET/CT fusion images, PET images and CT images of the same patient were analyzed frame by frame. TNM stage was analyzed based on PET/CT and CT. PET/CT-GTV and CT-GTV volume were analyzed. Results: 59 malignant lesions were detected by PET/CT in the 17 patients. Among 59 lesions, 31 lesions were detected and displayed definitely by both PET and the plain scan of CT; 23 lesions were detected definitely by PET but not by the plain scan of CT; while 5 lesions were negative by PET but definitely by the plain scan of CT. The sensitivity of PET/CT was higher than PET and the plain scan of CT alone. Changes in TNM stage occurred in 7 patients (41%), based on PET/CT. The median PET/CT-GTV and CT-GTV volume was 84.3 cm 3 (range, 46∼364 cm 3 ) and 116.2 cm 3 (range, 58∼472 cm 3 ), respectively, showed significant differences (p = 0.0005). Conclusions: PET/CT can increase the accuracy of the staging and defining target volumes for radiation therapy fields for head and neck cancer. No significant financial relationships to disclose.
춘계학술대회 : 포스터발표 ; 간암 : 폐 전이를 동반한 진행성 간세포암에서 지속적인 전신 5-FU 항암요법이 생존기간에 미치는 영향
Authors: 남성민, 유찬란, 우현영, 정승원, 장정원, 남순우, 배시현, 최종영, 윤승규, 조세현, 이창돈
Journal: Clinical and Molecular Hepatology (2007)
Neoplastic Transformations in Cells Explanted From the Kidneys of 3-Day-Old C3H Mice
Authors: William F. Andresen, Virginia J. Evans, Floyd M. Price, Thelma B. Dunn
Journal: JNCI Journal of the National Cancer Institute (1966)

To determine if the malignant transformation in vitro already described for cells isolated from minced mouse embryos would occur similarly in cells isolated from mouse kidneys, 3 series of cells from 3-day-old C3H/HeN mouse kidney were grown on chemically defined medium NCTC 135 supplemented with 10 percent v/v horse serum. Intraocular implants from the cells in vitro were made into mice of the same strain after progressively longer periods in culture, and the time at which tumors first appeared in the eye was determined. Tumors arose first from cells 145 days in vitro in series 1, 133 days in vitro in series 2, and 129 days in vitro in series 3. These times are comparable to those previously determined for cells from minced C3H mouse embryos grown under identical conditions. We thus conclude that the neoplastic conversion in vitro and the time required for this change are comparable to those of cells from minced C3H mouse embryos. The results also indicate that the time of neoplastic change in tissue culture is independent of the cell source and age of the animal . The development of apparently normal adipose tissue in the anterior chamber after transfer of cells from series 2 was also noted. This is part of a continuing study on neoplastic transformations in vitro.
Composition Studies on Tobacco. XLIV. Tumor-Promoting Activity of Subfractions of the Weak Acid Fraction of Cigarette Smoke Condensate&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: F G Bock, A P Swain, R L Stedman
Journal: JNCI Journal of the National Cancer Institute (1971)

Subfractions of the weak acid fraction of cigarette smoke condensate (CSC) were tested for tumorigenic activity in mice previously painted with 125 μg 7,12-dimethylbenz[a]anthracene (DMBA). In one experiment, the pH of the test solutions ranged from 5.7–6.0. In a second experiment, the pH range was 5.0–5.5. Before fractionation the weak acids were more active in the second experiment with the lower pH. The residue remaining after steam distillation was consistently active. The steam distillates and a synthetic steam distillate gave inconsistent results and probably do not contribute importantly to the carcinogenicity of CSC for mouse skin. In high concentrations, the unfractionated weak acids produced 2 tumors in a group of 50 mice that had not been previously exposed to DMBA. The weak acid fraction is thus a very weak complete carcinogen. Even so, a comparison of the tumor yields produced by DMBA alone, by the weak acids alone, and by combinations of both agents suggests that the weak acids acted as promoting agents. It was concluded that the promoting activity of the weak acid fraction of CSC depended primarily on the nonvolatile constituents and only slightly on volatile phenols and other constituents of the steam distillate.
Erlotinib (E), cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer—A phase I trial
Authors: A. N. Rodrigues, C. C. do Carmo, C. Viegas, F. Erlich, R. Lima, R. Martins, D. Hercenhorn, K. Fontão, I. A. Small, C. M. Ferreira
Journal: Journal of Clinical Oncology (2007)

5592 Background: Pre-clinical data indicates that inhibition of epidermal growth factor receptor (EGFR) potentiates the effect of RT. This phase I trial aimed to determine the maximal tolerated dose (MTD) of erlotinib, an oral EGFR tyrosine kinase inhibitor, when administered concurrently with standard chemoradiation (CRT) for cervical cancer. Methods: In a modified Fibonacci design, three cohorts of three patients received escalating doses of E (50/100/150 mg) one week before and combined with C (40 mg/m 2 , weekly, 5 cycles) and RT (external beam RT - 4,500 cGy in 25 fractions, followed by 4 fractions/600 cGy/weekly of brachytherapy). Eligibility criteria included histologically proven squamous cell cervical carcinoma, stage IIB to IIIB; no prior therapy; ECOG PS &lt;3 and adequate end-organ functions. Patients were allowed four additional weeks of toxicity observation after CRT + E before proceeding to the next cohort. Frozen tissue for molecular studies was collected before treatment. Results: Between 12/04 and 8/06, 15 patients were enrolled, 3 at dose level (DL) 50 mg, 4 at DL 100mg and 6 at DL 150 mg. Patients presented median age 47 (36–59), stage IIB (46,2%) and IIIB (53,8%). Overall E+CRT was well tolerated; 3 patients did not complete the planned schedule.One patient at DL 100mg withdrew informed consent due to grade 2 rash; at DL150mg one patient presented Raynaud’s Syndrome and had C interrupted and one patient presented grade 4 hepatotoxicity. The latter was interpreted as DLT and 3 additional patients were included in this cohort. No further grade 4 toxicity occured. Grade 3 toxicity occurred in 33% of the cases, being diarrhea in 3 patients, rash in 2 patients and leukopenia in 1 patient.It shoud be highlighted that E+CRT did not lead to limiting in-field toxicity (radiodermitis, rash or diarrhea). Within the 12 patients who received through E+CRT, median duration of treatment and follow-up was 70 (67–80) days and 9.5 (3–23) months, respectively. The phase II of this trial is ongoing. Conclusions: The MTD has been defined as 150 mg. This is the first report of a combination of erlotinib, cisplatin and pelvic RT. The addition of E to standard CRT does not appear to increase in-field or systemic toxicities. No significant financial relationships to disclose.
Dimethyl Sulfoxide-Induced Transglutaminase Activity in Murine-Derived Friend Erythroleukemia Cells
Authors: K H Hsu, H Friedman
Journal: JNCI Journal of the National Cancer Institute (1983)

Friend erythroleukemia cells (FL cells) derived from DBA/2 mice may be induced to differentiate in vitro by addition of dimethyl sulfoxide (DMSO) to the culture medium. Transglutaminase (glutaminyl-peptide gamma-glutamyltransferase, EC 2.3.2.13) (TGase) activity was detected in the lysates of uninduced FL cells and was markedly increased in DMSO-treated cells. DMSO induced TGase activity of differentiating FL cells in a dose-dependent manner over the concentration range 0-280 mM. The increase in TGase activity was observed after 1 day's cultivation of the cells with 280 mM DMSO and continued to 4 days. Another differentiation inducing agent, butyric acid (1.4 mM), was as effective as DMSO in enhancing TGase activity in FL cells. Treatment of controls, a lymphoma cell line and mouse erythrocytes, with DMSO or butyric acid had no effect. These results suggest that the increase in TGase activity in DMSO- or butyric acid-treated FL cells may be related to cell differentiation.
Fluidity of the Subsyndromal Phenomenology of Borderline Personality Disorder Over 16 Years of Prospective Follow-Up
Authors: Mary C. Zanarini, Frances R. Frankenburg, D. Bradford Reich, Garrett M. Fitzmaurice
Journal: American Journal of Psychiatry (2016)

The purpose of this study was to determine the cumulative rates of 2- and 4-year remission, and the recurrences that follow them, of 24 symptoms of borderline personality disorder over 16 years of prospective follow-up.A total of 290 inpatients meeting rigorous criteria for borderline personality disorder and 72 axis II comparison subjects were assessed during their index admission using a series of semistructured diagnostic interviews. The same instruments were readministered at eight contiguous 2-year time periods.The 12 acute symptoms (e.g., self-mutilation, help-seeking suicide attempts) of borderline personality disorder were more likely to remit for a period of 2 years and for a period of 4 years than the 12 temperamental symptoms (e.g., chronic anger/frequent angry acts, intolerance of aloneness) of this disorder. They were also less likely to recur after a remission lasting 2 years or a remission lasting 4 years.Taken together, the symptoms of borderline personality disorder are quite fluid, with remissions and recurrences being common. However, the more clinically urgent acute symptoms of borderline personality disorder seem to have a better prognosis than the less turbulent temperamental symptoms of the disorder.
Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study
Authors: Bobbi S Pritt, Paul S Mead, Diep K Hoang Johnson, David F Neitzel, Laurel B Respicio-Kingry, Jeffrey P Davis, Elizabeth Schiffman, Lynne M Sloan, Martin E Schriefer, Adam J Replogle, Susan M Paskewitz, Julie A Ray, Jenna Bjork, Christopher R Steward, Alecia Deedon, Xia Lee, Luke C Kingry, Tracy K Miller, Michelle A Feist, Elitza S Theel, Robin Patel, Cole L Irish, Jeannine M Petersen
Journal: The Lancet Infectious Diseases (2016)
Fluoropyrimidine biochemical modulation in colon cancer: pharmacology relevant in both the laboratory and the clinic.
Authors: J H Doroshow, E M Newman
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.3.365 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1999704 Fluoropyrimidine biochemical modulation in colon cancer: pharmacology relevant in both the laboratory and the clinic. J H DoroshowxJ H DoroshowSearch for articles by this author , E M NewmanxE M NewmanSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.3.365 First Page PDF © 1991 by American Society of Clinical Oncology
Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis
Authors: Jin Kyun Park, Andrea Fava, John Carrino, Filippo Del Grande, Antony Rosen, Francesco Boin
Journal: Arthritis & Rheumatology (2015)

Objective Bone resorption of distal phalanges, or acroosteolysis (AO), can develop in patients with systemic sclerosis (SSc), causing pain and functional limitation. This study was undertaken to investigate whether AO may be associated with abnormal osteoclastogenesis in SSc patients and whether hypoxia may be involved in this process. Methods Peripheral blood mononuclear cells (PBMCs) obtained from 26 SSc patients (11 with AO and 15 without AO) and 14 healthy controls were cultured in the presence of RANKL and macrophage colony‐stimulating factor for 9 days. Tartrate‐resistant acid phosphatase–positive multinucleated giant cells (MGCs) containing 3 or more nuclei were counted as osteoclasts. Plasma levels and effects of vascular endothelial growth factor (VEGF) on osteoclast formation were evaluated. Results SSc patients with AO formed significantly more osteoclasts after 9 days than did patients without AO (mean ± SD 142.4 ± 67.0 versus 27.2 ± 17.6 MGCs/well; P &lt; 0.001) or healthy controls (mean ± SD 18.7 ± 27.0 MGCs/well; P &lt; 0.001). No significant difference in osteoclast formation was noted between the patients without AO and healthy controls. Plasma levels of VEGF were higher in SSc patients with AO compared to those without (mean ± SD 142.4 ± 69.6 pg/ml versus 88.1 ± 38.2 pg/ml; P &lt; 0.005) or healthy controls (54.2 ± 24.6 pg/ml; P = 0.018). Priming with VEGF‐A for 24 hours significantly increased osteoclast generation by 5.3 ± 1.9 fold ( P = 0.0018). The radiographic extent of AO was associated with increased osteoclast formation (Spearman's ρ = 0.741, P = 0.01). Conclusion Our findings indicate that increased osteoclast formation and higher VEGF levels may contribute to AO in SSc patients. Further studies are needed to elucidate whether targeting osteoclastogenesis may provide a specific therapeutic option for SSc‐associated AO.
Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project.
Authors: R J Wyatt, B A Julian, R W Baehler, C C Stafford, R G McMorrow, T Ferguson, E Jackson, S Y Woodford, P M Miller, S Kritchevsky
Journal: Journal of the American Society of Nephrology (1998)

Population-based incidence data for IgA nephropathy (IgAN) are available for some countries but not for the United States. The purpose of this study was to determine the incidence of IgAN in central and eastern Kentucky for 5- and 10-yr periods between 1975 and 1994 and to examine differences among patient groups between those periods. The incidence of IgAN was 5.4 cases per one million population per year (MPPY) for period 1A (1975 through 1979), increasing to 12.4 cases per MPPY for period 2B (1990 through 1994) (P < 0.001). Males had a 2.7 times higher incidence than females for period 1 (1975 through 1984) and 2.2 times higher for period 2 (1985 through 1994). For period 1A, the incidence for Fayette County, which includes the city of Lexington, was lower than that of the rest of the study area (P=0.26), whereas for period 2 the incidence was higher for Fayette County (P=0.052). During period 1, the highest incidence of IgAN for any age and gender group was 24.3 cases per MPPY for males ages 30 through 39. For period 2, the incidence for males was similar for each decade between ages 20 and 59 (approximately 19 cases per MPPY). No African-American was diagnosed during period 1, but in period 2 incidences for blacks and whites were similar (10.7 and 10.2 cases per MPPY, respectively). For the last 5 yr of the study (1990 through 1994), the incidence of end-stage renal disease (ESRD) due to IgAN was 5.5 cases per MPPY: 8.4 for males and 2.7 for females. The incidence of IgAN in Kentucky for period 2B was still much lower than that in European studies, but the incidence of ESRD due to IgAN may be similar. Thus, IgAN may be as important a condition with respect to ESRD in Kentucky as it is in other regions of the world.
Biopsy—What’s in the Name?
Authors: Asfandyar Mufti, Robert Jackson
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI
Authors: Dominick J. Angiolillo, Francesco Franchi, Ron Waksman, Joseph M. Sweeny, Ganesh Raveendran, Renli Teng, Yonggang Zhao, Glenn Carlson, Naeem Khan, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
Disproportionately high fatality rate of women compared to men in patients with gemcitabine-associated lung injury: Preliminary findings from RADAR
Authors: N. Slimack, S. M. Belknap, K. R. Carson, T. M. Kuzel, S. Trifilio, P. R. Yarnold, D. W. Raisch, M. S. Tallman, C. L. Bennett
Journal: Journal of Clinical Oncology (2005)

6034 Background: The RADAR team has recently characterized the frequency, severity, clinical features and quality of reporting of gemcitabine-associated pulmonary injury. Several factors may increase severity of gemcitabine toxicity in women: mg/m2 dosing, gives a higher systemic exposure in women due to their lower lean body mass per m2. (2) women have less pulmonary reserve. (3) Women are more likely to receive combined therapy with gemcitabine and a taxane and taxanes appear to increase the severity of gemcitabine-associated lung injury. Methods: We obtained reports of gemcitabine-associated lung injury from Medwatch or the medical literature. The case definition included use of gemcitabine as cancer chemotherapy and clinical findings, laboratory evidence, or imaging studies suggestive of lung injury. We used logistic regression to analyze a data model with response variable being death and explanatory variables being female gender, age, duration of therapy, and reporting source (clinical trial, case report, spontaneous report). Results: After removal of duplicate and null reports, there were 178 patients with gemicitabine-associated lung injury. The fatality rate was 80% in women and 55% in men. Female gender was associated with death in this cohort of patients with gemcitabine-associated lung injury with a high degree of statistical significance. Conclusions: Logistic regression analysis of fatalaties among 178 patients with gemcitabine-associated lung injury found a highly statistically significant association with female gender. Comparative pharmacokinetics of gemcitabine in women and men and metaanalysis of prospectively gathered gemcitabine toxicity data is warranted. No significant financial relationships to disclose.